Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

FBRX

Forte Biosciences Inc

Dec 11 • 02:34PM ET

24.50

Dollar change +0.99
Percentage change 4.21	%

Healthcare • Biotechnology • USA • NASD

Peers: FOLD MRNS AGEN CYCC CGEM GERN AKBA CLSD ARMP DYAI

| Held by: ONEQ VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.39	Insider Own	12.62%	Shs Outstand	1.46M	Perf Week	8.89%
Market Cap	35.82M	Forward P/E	-	EPS next Y	-3.81	Insider Trans	13.90%	Shs Float	1.28M	Perf Month	353.70%
Income	-34.20M	PEG	-	EPS next Q	-2.07	Inst Own	53.88%	Short Float	16.50%	Perf Quarter	249.50%
Sales	0.00M	P/S	-	EPS this Y	58.65%	Inst Trans	-6.03%	Short Ratio	0.40	Perf Half Y	71.93%
Book/sh	6.42	P/B	3.82	EPS next Y	63.19%	ROA	-103.90%	Short Interest	0.21M	Perf Year	60.66%
Cash/sh	11.19	P/C	2.19	EPS next 5Y	-	ROE	-137.40%	52W Range	4.11 - 28.68	Perf YTD	19.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	51.36%	ROI	-365.10%	52W High	-14.57%	Beta	1.13
Dividend TTM	-	Quick Ratio	2.06	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	496.11%	ATR (14)	2.87
Dividend Ex-Date	-	Current Ratio	2.06	EPS Y/Y TTM	37.42%	Oper. Margin	-	RSI (14)	72.10	Volatility	16.96% 22.33%
Employees	9	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	81.33
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	30.90%	Payout	-	Rel Volume	0.23	Prev Close	23.51
Sales Surprise	-	EPS Surprise	28.32%	Sales Q/Q	-	Earnings	Nov 14 AMC	Avg Volume	528.23K	Price	24.50
SMA20	42.22%	SMA50	150.98%	SMA200	92.07%	Trades		Volume	94,542	Change	4.21%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$2.75
Sep-20-21	Upgrade	Chardan Capital Markets	Sell → Buy	$4 → $3.50
Sep-03-21	Downgrade	Truist	Buy → Hold	$4
Sep-03-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-03-21	Downgrade	Chardan Capital Markets	Buy → Sell	$105 → $4
Sep-03-21	Downgrade	B. Riley Securities	Buy → Neutral	$3
May-14-21	Initiated	B. Riley Securities	Buy	$73
Mar-26-21	Initiated	Citigroup	Buy	$75
Aug-28-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$45
Aug-25-20	Initiated	Truist	Buy	$70

Nov-25-24 09:00AM	Forte Biosciences to Host RandD Day December 3, 2024 (Business Wire)
09:00AM	Forte Biosciences to Host R&D Day December 3, 2024 (Business Wire)
Nov-20-24 09:00AM	Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications (Business Wire) +128.69%
Nov-14-24 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update (Business Wire)
Aug-26-24 11:51AM	Upcoming Stock Splits This Week (August 26 to August 30) Stay Invested (TipRanks) +6.44%
09:54PM	Loading…
Aug-14-24 09:54PM	FBRX Stock Earnings: Forte Biosciences Misses EPS for Q2 2024 (InvestorPlace) -7.80% -20.51%
04:01PM	Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update (Business Wire)
Jul-15-24 10:26AM	Is Forte Biosciences, Inc. (FBRX) One of the Best Penny Stocks to Buy Now Under $1? (Insider Monkey)
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
May-17-24 04:05PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
May-13-24 09:54PM	FBRX Stock Earnings: Forte Biosciences Reported Results for Q1 2024 (InvestorPlace)
04:05PM	Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update (Business Wire)
Mar-25-24 12:00PM	What Makes Forte Biosciences (FBRX) a New Buy Stock (Zacks)
Mar-19-24 06:53AM	FBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023 (InvestorPlace)
Mar-18-24 04:05PM	Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update (Business Wire)
07:21AM	Loading…
Dec-04-23 07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Dec-01-23 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire) +5.06%
Nov-13-23 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update (Business Wire) -9.47%
Sep-14-23 10:50AM	ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Companys Upcoming Annual Meeting (Business Wire)
Sep-06-23 03:15PM	Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Companys Boardroom (Business Wire)
Aug-25-23 08:00AM	Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders (Business Wire)
Aug-14-23 04:01PM	Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update (Business Wire) -6.93%
Aug-01-23 04:01PM	Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102 (Business Wire) -5.65%
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire)
May-19-23 04:01PM	Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules (Business Wire)
May-15-23 04:01PM	Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update (Business Wire)
Mar-31-23 04:05PM	Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update (Business Wire)
Jan-12-23 04:05PM	Mr. David Gryska Appointed to Forte Biosciences Board of Directors (Business Wire)
Nov-14-22 04:01PM	Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update (Business Wire)
04:01PM	Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors (Business Wire)
08:00AM	Loading…
Aug-17-22 08:00AM	Camac Partners Condemns Forte Biosciences Seemingly Defensive and Unjustifiable Capital Raise (Business Wire)
Aug-15-22 04:05PM	Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update (Business Wire)
Jul-08-22 07:16AM	We're Keeping An Eye On Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate (Simply Wall St.) +6.99%
Jun-07-22 09:00AM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) +10.17%
09:00AM	Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President (Business Wire)
May-16-22 09:00AM	Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update (Business Wire) -8.90%
Dec-15-21 05:55AM	Here's Why We're Watching Forte Biosciences' (NASDAQ:FBRX) Cash Burn Situation (Simply Wall St.) -5.16%
Sep-09-21 06:15PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. FBRX (GlobeNewswire)
Sep-08-21 08:51AM	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm (Business Wire)
Sep-07-21 09:40PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. FBRX (ACCESSWIRE) -17.19%
Sep-06-21 12:42PM	INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm (Newsfile)
Sep-03-21 07:42PM	INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm (Business Wire) -82.30% -17.19%
02:14PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX (PR Newswire)
11:15AM	Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Forte Biosciences, Inc. (FBRX) Investigation (ACCESSWIRE)
Sep-02-21 04:05PM	Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance (Business Wire)
Aug-16-21 04:05PM	Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7 (Business Wire) -6.11% +12.23%
Aug-02-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
Jul-12-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) -7.72%
Jul-07-21 10:02AM	Implied Volatility Surging for Forte Biosciences (FBRX) Stock Options (Zacks) -7.57%
Jul-01-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
May-14-21 03:06AM	Read This Before Selling Forte Biosciences, Inc. (NASDAQ:FBRX) Shares (Simply Wall St.)
May-10-21 04:05PM	Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update (Business Wire)
02:30PM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)
May-03-21 04:30PM	Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update (Business Wire) -5.36%
Mar-25-21 08:42AM	Forte Posts Lower-Than-Feared Quarterly Loss; Shares Drop 9.5% (SmarterAnalyst) +15.63%
Mar-24-21 08:00AM	Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update (Business Wire) -9.52%
06:30AM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)
Mar-17-21 04:05PM	Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update (Business Wire) -5.36%
Feb-23-21 04:01PM	Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th (Business Wire)
Feb-18-21 04:01PM	Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st (Business Wire) -9.24% +5.27%
Feb-13-21 03:18AM	What Kind Of Investors Own Most Of Forte Biosciences, Inc. (NASDAQ:FBRX)? (Simply Wall St.)
Feb-12-21 04:01PM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire)
Dec-02-20 11:26PM	Is Forte Biosciences (FBRX) A Good Stock To Buy Now? (Insider Monkey) +5.81%
Nov-24-20 04:05PM	Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd (Business Wire) -5.33%
Nov-16-20 04:05PM	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules (Business Wire) +11.24%
Nov-15-20 09:00AM	Read This Before Selling Forte Biosciences, Inc. (NASDAQ:FBRX) Shares (Simply Wall St.)
Nov-10-20 04:05PM	Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th (Business Wire)
Nov-09-20 04:05PM	Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update (Business Wire)
02:30PM	Forte Biosciences Inc to Host Earnings Call (ACCESSWIRE)
Nov-02-20 04:30PM	Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9 (Business Wire) -9.69%
04:05PM	Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Oct-29-20 08:00AM	Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock (Business Wire) +26.94%
Oct-28-20 04:09PM	Forte Biosciences Announces Proposed Public Offering of Common Stock (Business Wire) -15.51%
Oct-26-20 08:30AM	Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis (Business Wire)
Sep-29-20 09:00AM	Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis (Business Wire)
Sep-16-20 08:48AM	We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely (Simply Wall St.) +5.05%
Sep-09-20 04:01PM	Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine (Business Wire) +9.47% +11.13%
Aug-25-20 08:30AM	Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules (Business Wire) +6.32%
Aug-10-20 04:00PM	Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update (Business Wire) +8.66% -13.82%
Aug-03-20 09:00AM	Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10 (Business Wire) +6.15%
Jul-28-20 08:30AM	Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules (Business Wire) -5.07%
Jun-18-20 08:30AM	Forte Biosciences, Inc. Announces Issuance of New U.S. Patent (Business Wire) -10.83%

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Riley Antony A	CHIEF FINANCIAL OFFICER	Nov 21 '24	Buy	5.55	22,514	124,998	30,776	Nov 22 05:45 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Oct 01 '24	Option Exercise	0.00	375	0	8,395	Oct 02 06:21 PM
Wagner Paul A.	SEE REMARKS	Oct 01 '24	Option Exercise	0.00	1,250	0	77,568	Oct 02 06:19 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Jul 01 '24	Option Exercise	0.00	9,375	0	203,849	Jul 03 12:18 PM
Wagner Paul A.	SEE REMARKS	Jul 01 '24	Option Exercise	0.00	31,250	0	1,910,424	Jul 03 12:17 PM
Riley Antony A	CHIEF FINANCIAL OFFICER	Apr 01 '24	Option Exercise	0.00	9,375	0	197,819	Apr 02 06:32 PM
Wagner Paul A.	SEE REMARKS	Apr 01 '24	Option Exercise	0.00	31,250	0	1,881,627	Apr 02 06:31 PM
Chen Hubert C	See remarks	Jan 01 '24	Option Exercise	0.00	7,500	0	96,478	Jan 03 04:04 PM
Riley Antony A	Chief Financial Officer	Jan 01 '24	Option Exercise	0.00	9,375	0	192,285	Jan 03 04:02 PM
Wagner Paul A.	See Remarks	Jan 01 '24	Option Exercise	0.00	31,250	0	1,854,486	Jan 03 04:01 PM
Wagner Paul A.	See Remarks	Dec 18 '23	Buy	0.75	10,000	7,525	1,823,236	Dec 20 10:56 AM
Wagner Paul A.	See Remarks	Dec 13 '23	Buy	0.70	10,520	7,351	1,803,236	Dec 15 06:29 PM
Wagner Paul A.	See Remarks	Dec 14 '23	Buy	0.72	10,000	7,200	1,813,236	Dec 15 06:29 PM
Wagner Paul A.	See Remarks	Dec 12 '23	Buy	0.65	4,776	3,088	1,792,716	Dec 12 07:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FBRX

Forte Biosciences Inc

Upgrade your FINVIZ experience